Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Emergent Biosolutions (NY: EBS )

9.316 +0.016 (+0.17%)
Streaming Delayed Price Updated: 10:12 AM EDT, Jul 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 783,836
Open 9.500
Bid (Size) 9.300 (2)
Ask (Size) 9.330 (3)
Prev. Close 9.300
Today's Range 9.130 - 9.740
52wk Range 1.420 - 9.300
Shares Outstanding 52,400,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Johnson & Johnson Faces MedTech Challenges But Is 'On Track' To Meet 2024 Guidance: Goldman Sachs
Johnson & Johnson is set to release its Q2 2024 earnings on July 17. Analysts estimate $22.29 billion in sales and an EPS of $2.71. 
Via Benzinga
Emergent BioSolutions And Johnson & Johnson Resolve Claims Over COVID-19 Vaccine Manufacturing
Emergent BioSolutions and Janssen Pharmaceuticals settle disputes over SARS-CoV-2 vaccine manufacturing with a $50 million agreement, resolving all related claims and arbitration. 
Via Benzinga
Exposures COVID-19

Performance

YTD
+259.68%
+259.68%
1 Month
+45.79%
+45.79%
3 Month
+317.75%
+317.75%
6 Month
+329.30%
+329.30%
1 Year
+27.96%
+27.96%

More News

Read More
Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan
From Emergent BioSolutions
Via GlobeNewswire
Why Is Vaccine Maker Emergent BioSolutions Stock Trading Higher On Tuesday?
Via Benzinga
Key Takeaways From Emergent BioSolutions Analyst Ratings
Via Benzinga
Looking Into Emergent BioSolutions's Recent Short Interest
Via Benzinga
Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
From Emergent BioSolutions
Via GlobeNewswire
7 Top Stocks Under $10: June 2024 Edition
Via InvestorPlace
What Is Going On With Emergent BioSolutions Shares?
Via Benzinga
Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness Day
From Emergent BioSolutions
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
7 Stocks to Buy Immediately Following Strong Earnings
Via InvestorPlace
Vice Stock Vanguards: 3 Sin Stocks Delivering Heavenly Returns
Via InvestorPlace
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024
From Emergent BioSolutions
Via GlobeNewswire
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Via Benzinga
Emergent BioSolutions Reports Blockbuster Q1 Results, Raises Guidance: What's Going On With The Stock?
Via Benzinga
Nasdaq Gains Over 200 Points; Dentsply Sirona Shares Fall After Q1 Results
Via Benzinga
Dow Surges Over 100 Points; ConocoPhillips Earnings Miss Views
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
MercadoLibre Stock Split: Will MELI Investors See Wishes Come True Today?
Via InvestorPlace
JPMorgan Just Raised Its Price Target on Carvana (CVNA) Stock
Via InvestorPlace
Emergent BioSolutions Layoffs 2024: What to Know About the Latest EBS Job Cuts
Via InvestorPlace
Topics Workforce
Exposures Layoff
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.